美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Militia Long/Short Equity ETF

36.22

-0.2800-0.77%

盤後：36.220.00000.00%19:49 EDT

成交量：10.66萬

成交額：386.61萬

市值：3.72億

市盈率：- -

高：36.40

開：36.36

低：36.05

收：36.50

52周最高：39.39

52周最低：27.93

股本：1,028.00萬

流通股本：1,028.00萬

量比：1.01

換手率：1.04%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Alpha Tau新型放射療法在美國完成臨床試驗患者招募

环球市场播报

核藥「狂飆」：2026年中外巨頭激戰300億美元藍海

21世纪经济报道

營收按年下降33.8%，基石藥業押注三抗管線進展如何？

21世纪经济报道

科賽優®在華獲批用於治療伴有症狀、無法手術的叢狀神經纖維瘤的1型神經纖維瘤病（NF1-PN）兒童及成人患者

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ORR"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":36.22,"timestamp":1779480000000,"preClose":36.5,"halted":0,"volume":106583,"hourTrading":{"tag":"盘后","latestPrice":36.22,"preClose":36.22,"latestTime":"19:49 EDT","volume":589,"amount":21332.73,"timestamp":1779493772175,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.00767123287671236,"floatShares":10280000,"shares":10280000,"eps":0,"marketStatus":"美國陣亡戰士紀念日休市","change":-0.28,"latestTime":"05-22 16:00:00 EDT","open":36.36,"high":36.4,"low":36.045,"amount":3866128,"amplitude":0.009726,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":36.5,"sharesOutstanding":12900000,"nav":36.35,"aum":368952500,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":36.22,"preClose":36.22,"latestTime":"19:49 EDT","volume":589,"amount":21332.73,"timestamp":1779493772175,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0059086728774986,"impliedVol":0.2362,"impliedVolPercentile":0.9158},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":10280000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.0059086728774986,"shares":10280000,"dividePrice":0,"high":36.4,"amplitude":0.009726,"preClose":36.5,"low":36.045,"week52Low":27.93,"pbRate":"--","week52High":39.39,"institutionHeld":0,"latestPrice":36.22,"eps":0,"divideRate":0,"volume":106583,"delay":0,"ttmEps":0,"open":36.36,"prevYearClose":34.16,"prevWeekClose":36.22,"prevMonthClose":36.03,"prevQuarterClose":36.45,"fiveDayClose":36.59,"twentyDayClose":35.79,"sixtyDayClose":38.96},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633451996","title":"Alpha Tau新型放射療法在美國完成臨床試驗患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=2633451996","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633451996?lang=zh_tw&edition=fundamental","pubTime":"2026-05-08 21:07","pubTimestamp":1778245620,"startTime":"0","endTime":"0","summary":"以色列医疗企业Alpha Tau Medical Ltd．今日宣布，其评估新型放射疗法Alpha DaRT治疗复发性皮肤鳞状细胞癌的美国多中心关键临床试验已完成全部88名患者招募。这标志着该疗法向获取美国食品和药物管理局上市前审批迈进重要阶段。Alpha DaRT疗法旨在通过靶向肿瘤内放射机制提供局部治疗。　　Alpha Tau公司首席执行官乌齐·索费尔指出，完成此次美国关键试验的患者招募是推动该疗法迈向商业化的核心环节。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-08/doc-inhxfamz4237008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627491097","title":"核藥「狂飆」：2026年中外巨頭激戰300億美元藍海","url":"https://stock-news.laohu8.com/highlight/detail?id=2627491097","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627491097?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 12:54","pubTimestamp":1776142440,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛2026年的春天，核药赛道没有一丝“倒春寒”的迹象。4月中旬，两则消息几乎同时引爆了全球核医学圈。一则是关于“中国原创”的崛起：百洋医药集团孵化企业瑞迪奥研发的99mTc-3PRGD2（吉伦泰）正式获批，这是全球首个用于SPECT显像的广谱肿瘤显像剂，打破了PET技术近30年的垄断。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704207863.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704207863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4161","ORR","CR","HCC","BK4006","RDC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624601597","title":"營收按年下降33.8%，基石藥業押注三抗管線進展如何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2624601597","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624601597?lang=zh_tw&edition=fundamental","pubTime":"2026-04-01 18:50","pubTimestamp":1775040648,"startTime":"0","endTime":"0","summary":"继2024年上半年首次实现盈利、全年财务业绩持续改善后，基石药业（2616.HK）2025年业绩再度下滑。年报显示，公司2025年实现收入2.7亿元，同比下降33.8%；年内亏损扩大至4.37亿元，较2024年的0.91亿元亏损增加3.46亿元。在业绩承压的背景下，基石药业同步披露了PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新开发进展及I/II期关键临床数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604013692073178.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604013692073178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","LU0053666078.USD","ORR","LU0210528500.USD","BK4588","BK4107","LU2487616109.SGD","L"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623539793","title":"科賽優®在華獲批用於治療伴有症狀、無法手術的叢狀神經纖維瘤的1型神經纖維瘤病（NF1-PN）兒童及成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2623539793","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623539793?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 15:46","pubTimestamp":1774856760,"startTime":"0","endTime":"0","summary":"成为国内首个且唯一*获批用于3岁及3岁以上该患者人群的治疗药物 上海2026年3月30日 /美通社/ -- 阿斯利康宣布，中国国家药品监督管理局已正式批准科赛优，一种选择性、口服MEK抑制剂，用于3岁及3岁以上伴有症状、无法手术的丛状神经纤维瘤的1型神经纤维瘤病儿童及成人患者的治疗[1]。司美替尼已在美国、欧盟、日本、中国及其他国家/地区获批，用于治疗特定伴有症状且无法手术切除PN的 NF1 儿童患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4922084_ZH22084_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0320765992.SGD","LU1829250122.USD","LU2417539215.USD","BK4007","BK4585","LU2462157665.USD","AZN","BK4588","LU0889565916.HKD","LU2456880835.USD","LU0058720904.USD","BK4096","PN","BK4568","ORR","LU0289739699.SGD","IE00B3T34201.USD","LU2236285917.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":7,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}